Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China

作者
Zhenyu Niu,Jianchun Wang,Jingru Ren,Liu R,J Z Guo,Nan Zhang,Yiming Zheng,Hongjun Hao,Feng Gao,Haiqiang Jin
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:17: 1752846-1752846 被引量:1
标识
DOI:10.3389/fimmu.2026.1752846
摘要

Objective: This study aimed to evaluate the real-world efficacy, safety, and application patterns of efgartigimod in Chinese patients with generalized myasthenia gravis (gMG), with a focus on individualized treatment strategies. Methods: We conducted a single-center, retrospective analysis of 81 gMG patients who received at least one standard cycle of efgartigimod (10 mg/kg weekly for 4 weeks). Disease severity was assessed using Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Composite (MGC) scores at baseline, week 2, and week 4. Retreatment and regimen modifications were individualized, which included exploration of a reduced-frequency regimen (2 infusions every 2 weeks) in selected patients. Results: In the overall cohort, 65 (80.25%) and 63 (77.78%) patients achieved MG-ADL (reduction ≥2) and QMG (reduction ≥3) responses, respectively, after the first cycle. 65 (80.25%) patients received only one cycle; among them, 41 (63.07%) maintained disease control with concomitant immunosuppressive therapies without requiring additional efgartigimod. The 16 patients receiving multiple cycles (≥2) had higher baseline disease severity (higher Myasthenia Gravis Foundation of America class, MG-ADL, and QMG scores) and showed progressive improvement with flexible retreatment. In a selected subgroup of 9 patients (based on age, robust response, and significant IgG reduction), a reduced-frequency regimen (2 infusions every 2 weeks) maintained efficacy while reducing the infusion burden. Adverse events were mostly mild, with no new safety signals. Interpretation: Efgartigimod demonstrated rapid and broad efficacy in a real-world gMG cohort. An "induction-maintenance" strategy, using efgartigimod for acute control and conventional immunosuppressants for long-term management, proved effective in most patients. A reduced-frequency regimen may be feasible in selected cases, highlighting the value of individualized treatment approaches in optimizing outcomes and reducing treatment burden.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
早安完成签到,获得积分10
1秒前
CML完成签到,获得积分10
1秒前
SS完成签到 ,获得积分10
1秒前
ppp发布了新的文献求助10
1秒前
1秒前
3秒前
xujiahao完成签到,获得积分10
3秒前
Shen完成签到,获得积分10
3秒前
赫里迩斯完成签到,获得积分20
4秒前
Ikun完成签到,获得积分10
4秒前
595完成签到,获得积分10
4秒前
小巧的白竹完成签到,获得积分10
4秒前
大力的冬萱完成签到,获得积分0
5秒前
rui完成签到 ,获得积分10
7秒前
7秒前
欣慰的舞仙完成签到,获得积分10
8秒前
诺奇完成签到,获得积分10
9秒前
mumu完成签到 ,获得积分10
9秒前
美满的机器猫完成签到,获得积分10
9秒前
典雅浩轩完成签到,获得积分10
9秒前
贤惠的人龙完成签到,获得积分10
10秒前
zdk完成签到,获得积分10
11秒前
11秒前
跳跃芷蕊完成签到,获得积分10
12秒前
Hiraeth完成签到 ,获得积分10
12秒前
yunfan完成签到,获得积分10
12秒前
728完成签到,获得积分10
14秒前
xhtnt97完成签到 ,获得积分10
14秒前
吉吉国王完成签到,获得积分10
14秒前
开朗大雁完成签到 ,获得积分10
15秒前
笑对人生完成签到 ,获得积分10
15秒前
11完成签到,获得积分10
16秒前
Antonio完成签到 ,获得积分0
16秒前
Only完成签到 ,获得积分10
16秒前
高石完成签到 ,获得积分10
16秒前
Thesimp完成签到 ,获得积分10
17秒前
果果完成签到 ,获得积分10
18秒前
19秒前
19秒前
零点完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923